2月28日，永泰生物-B (06978) 发布公告，更新其核心产品候选药物EAL®的最新进展。根据近期与中国国家药品监督管理局药品审评中心(CDE)的沟通，CDE已同意公司提交EAL®的附条件批准申请。

EAL®是一种广谱性细胞免疫治疗产品，主要用于癌症治疗，具有超过十年的临床应用历史。该产品通过专利方法从患者自体外周血中提取T细胞，经过活化、扩增培育而成，主要活性成分为CD8+杀伤性T细胞。截至目前，公司已完成EAL®的II期临床试验。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.